Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lyfgenia
Pharma
Once valued at $10B, struggling bluebird bio sold for $29M
Private equity firms Carlyle and SK Capital have agreed to pay $29 million to acquire struggling gene therapy innovator bluebird bio.
Kevin Dunleavy
Feb 21, 2025 10:56am
Bluebird bio lays off 25% of workforce
Sep 24, 2024 10:19am
Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia
Aug 14, 2024 12:07pm
HHS provides unfavorable opinion on bluebird's fertility program
Jul 22, 2024 5:26pm
With 64 centers activated, bluebird is ready to grow Lyfgenia
May 9, 2024 1:40pm
Bluebird discusses Lyfgenia launch details and accounting errors
Mar 26, 2024 10:49am
